Septerna (SEPN) Current Deferred Tax Assets (2023 - 2025)

Septerna (SEPN) posted quarterly Current Deferred Tax Assets of $39000.0 for Q2 2025, little changed quarter-over-quarter from $39000.0 in Q1 2025.

Septerna (SEPN) Current Deferred Tax Assets (2023 - 2025) Analysis & Trends

Septerna's Current Deferred Tax Assets history runs 3 years deep, the most recent figure standing at $39000.0 for Q2 2025.

In Q2 2025, Current Deferred Tax Assets changed N/A year-over-year to $39000.0; the TTM figure through Jun 2025 stood at $39000.0 (changed N/A YoY), while the FY2024 annual figure was $39000.0, down 48.0% from the prior year.
Current Deferred Tax Assets for Q2 2025 stood at $39000.0, roughly flat from $39000.0 in the prior quarter.
The five-year high for Current Deferred Tax Assets was $232000.0 in Q3 2024, with the low at $39000.0 in Q4 2024.
The 3-year median for Current Deferred Tax Assets is $39000.0 (2024), against an average of $84800.0.
Peak annual rise in Current Deferred Tax Assets reached 48.0% in 2024, while the deepest fall reached 48.0% in 2024.
Septerna's Current Deferred Tax Assets stood at $75000.0 in 2023, then sank by 48.0% to $39000.0 in 2024, then changed by 0.0% to $39000.0 in 2025.
Business Quant data shows SEPN's Current Deferred Tax Assets at $39000.0 in Q2 2025, $39000.0 in Q1 2025, and $39000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Septerna	2.08 Bn	2.08 Bn	-

Download Data